TSE:RBM Response Biomedical (RBM) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free RBM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume1,707 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Response Biomedical alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Response Biomedical Stock (TSE:RBM)Response Biomedical Corp. (Response) offers diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets. The Company operates through the research, development, commercialization and distribution of diagnostic technologies segment. The Company develops, manufactures and sells its RAMP system for the global medical point of care market, including cardiovascular testing, infectious disease testing market and the on-site environmental testing market, including biodefense and vector environmental testing. In the United States, its RAMP 200 Reader is limited to central-lab use with the cardiovascular tests. POC, on-site diagnostic tests (or assays) are non-laboratory-based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. The Company's RAMP system is a platform technology that combines a fluorescence detection system with lateral flow immunoassays.Read More Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. RBM Stock News HeadlinesAugust 25, 2022 | apnews.comBisk Announces Contract Renewal with the USF Health Morsani College of MedicineAugust 12, 2022 | apnews.comPOINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business HighlightsApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.July 28, 2022 | finance.yahoo.comGlobal Genomic Cancer Panel and Profiling Market Research Report 2022July 9, 2022 | finance.yahoo.comMolecular Diagnostics for Cancer Market Report 2022: Featuring Key Players Abbott Diagnostics, Bristol-Myers Squibb, Janssen Diagnostics & OthersJuly 7, 2022 | finance.yahoo.comEmergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for EbolaJune 24, 2022 | yahoo.comEmergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine CandidateJune 15, 2022 | finanznachrichten.deDelveInsight Business Research, LLP: Age-related Macular Degeneration Market to Progress at a CAGR of 3.4% by 2032 | DelveInsightApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.June 15, 2022 | benzinga.comAge-related Macular Degeneration Market to...March 30, 2022 | finance.yahoo.comGlobal Liquid Biopsy Market Research Report 2022: Liquid Biopsy Enters Exponential Growth Phase as Pandemic SubsidesMarch 1, 2022 | yahoo.comCompany Announcement No. 01/2022January 29, 2022 | finance.yahoo.comOutlook on the Genomic Cancer Panel and Profiling Global Market - Featuring 10x Genomics, Abbott Diagnostics and AccuraGen Among OthersJanuary 15, 2022 | finance.yahoo.comWorld Genomic Cancer Panel and Profiling Market Research Report 2022 - Next Generation Sequencing Fuels a RevolutionJanuary 2, 2022 | benzinga.comLiquid Biopsy Markets 2022-2026 by Cancer, Usage, Biomarker, Place, & Product With Price and Volume OutlookOctober 14, 2021 | prnewswire.comWorld Liquid Biopsy Markets Report 2021: Liquid Biopsy Progress Delayed by COVID Pandemic but HugeOctober 14, 2021 | finance.yahoo.comUS Companion Diagnostic Markets 2021-2025 - CDs are Poised to Revolutionize the Diagnostics IndustryAugust 30, 2021 | ca.finance.yahoo.comFedEx Makes 5m RMB Grant to Henan Flood Relief EffortAugust 29, 2021 | msn.comChina Box Office: ‘Free Guy’ Opens to $23.8 MillionAugust 29, 2021 | benzinga.comJinjiang, China: Speeding Up to Build the City of SportsAugust 29, 2021 | yahoo.com‘Free Guy’ Flies To $100M+ Overseas With China Assist, Global Now $180M – International Box OfficeAugust 27, 2021 | markets.businessinsider.comQeeka Home 2021 Interim Revenue Up 66.5% to 524 Million RMBAugust 26, 2021 | msn.comBRIEF-Xpeng Reports Q2 Net Loss Per ADS At RMB 1.50August 26, 2021 | msn.comBRIEF-Yatsen Reports Q2 Net Loss Per Diluted ADS at RMB 0.62August 25, 2021 | seekingalpha.comMicro Bitcoin Futures: A Nifty New Tool For Traders And SpeculatorsAugust 25, 2021 | msn.comNo Stretcher At Rajasthan Hospital, Relatives Take Patients To Emergency Ward in AutoAugust 25, 2021 | msn.comBRIEF-Lexinfintech Holdings Reports Q2 Revenue Of RMB 3.269 BlnSee More Headlines Receive RBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Response Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorManufacturing Industry Electronic Computer Manufacturing Sub-IndustryN/A Current SymbolTSE:RBM CUSIPN/A CIKN/A Webwww.responsebio.com Phone+1-604-4566010FaxN/AEmployees147,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key Competitors(EDW.V)CVE:EDW(FSN.V)CVE:FSN(FTE.V)CVE:FTE108946 (AUA.V)CVE:AUA111040 (DNI.V)CVE:DNIView All Competitors RBM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Response Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Response Biomedical investors own include Marston's (MARS), Hornby (HRN) and Aston Martin Lagonda Global (AML). How do I buy shares of Response Biomedical? Shares of RBM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:RBM) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Response Biomedical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
